PTCT
PTC Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +10.0% ·
share flow +3.1% ·
net new positions +9.1%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 113 | +8 | 59.00M | $4.80B | +13 | −7 |
| Q1 2026 | 110 | -8 | 65.31M | $4.45B | +9 | −18 |
| Q4 2025 | 117 | 0 | 67.93M | $5.16B | +1 | — |
| Q3 2025 | 22 | +2 | 38.04M | $2.33B | +2 | — |
| Q2 2025 | 17 | 0 | 34.63M | $1.69B | +1 | −1 |
| Q1 2025 | 14 | +2 | 16.93M | $862.87M | +2 | — |
| Q4 2024 | 12 | 0 | 14.84M | $670.12M | — | — |
| Q3 2024 | 11 | -2 | 14.00M | $519.42M | — | −2 |
| Q2 2024 | 13 | — | 14.28M | $436.54M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 8.29M | -6.3% | $508.70M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 7.13M | -4.7% | $437.62M | 0.0% | ▼ Trim | 2 | SEC ↗ ×18 |
| 3 | Wellington Management ✦ | 4.92M | +4.8% | $301.86M | 0.1% | ▲ Add | 6 | SEC ↗ ×8 |
| 4 | State Street Global Advisors ✦ (passive) | 3.13M | +4.6% | $192.38M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 2.17M | -10.8% | $133.46M | 0.1% | ▼ Trim | 6 | SEC ↗ ×3 |
| 6 | Geode Capital Management ✦ (passive) | 1.95M | +0.8% | $119.74M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 1.73M | +88.0% | $106.23M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Fidelity (FMR) ✦ | 1.61M | -6.2% | $98.91M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 9 | Point72 Asset Management ✦ | 1.22M | New | $74.91M | 0.2% | New | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 1.06M | +174.8% | $64.84M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 11 | JPMorgan Chase ✦ | 981.87K | — | $60.26M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 12 | Renaissance Technologies ✦ | 927.30K | -3.7% | $56.91M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 13 | Goldman Sachs Group ✦ | 876.41K | — | $53.79M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | T. Rowe Price ✦ | 458.33K | +1.0% | $28.13M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 15 | Morgan Stanley ✦ | 419.42K | — | $25.74M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 16 | AQR Capital Management ✦ | 331.26K | -38.3% | $20.33M | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 17 | Arrowstreet Capital ✦ | 323.55K | +851.6% | $19.86M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | Adage Capital Partners ✦ | 291.00K | -52.0% | $17.86M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Marshall Wace ✦ | 157.74K | -70.7% | $9.68M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 20 | Two Sigma Investments ✦ | 24.34K | -52.1% | $1.49M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 18.06K | -49.3% | $1.11M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 22 | Bridgewater Associates ✦ | 11.94K | New | $732,635 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $74.91M | 0.2% |
| Bridgewater Associates | $732,635 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 348 holders, 95.15M shares, $6.33B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 53 sh · $3,389
Director · 2.45K sh · $155,091
Officer · 435 sh · $27,910
Officer · 1.64K sh · $104,881
Director · 376 sh · $25,737
Director · 9.62K sh · $652,796
Director · 2.99K sh · $199,341
Director · 7.01K sh · $471,854
Director · 10.00K sh · $673,400
Director · 9.43K sh · $639,124
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology